Hongliang Xin

Hongliang Xin

Auto-generated profile, based on publicly available information

Hongliang Xin

Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in ACS Nano
Verified
Journal Article
Closed access
WLWei Lv
Wei Lv
JXJianpei Xu
Jianpei Xu
XWXiaoqi Wang
Xiaoqi Wang
XLXinrui Li
Xinrui Li
QXQunwei Xu
Qunwei Xu
HXHongliang Xin
Hongliang Xin

24 July 2019 in ACS Nano
Verified
Journal Article
Closed access
JXJianpei Xu
Jianpei Xu
XWXiaoqi Wang
Xiaoqi Wang
HYHaoyuan Yin
Haoyuan Yin
XCXiang Cao
Xiang Cao
QHQuanyin Hu
Quanyin Hu
HXHongliang Xin
Hongliang Xin

1 July 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
YZYue Zhao
Yue Zhao
YJYan Jiang
Yan Jiang
WLWei Lv
Wei Lv
ZWZhongyuan Wang
Zhongyuan Wang
LLLingyan Lv
Lingyan Lv
ZGZhen Gu
Zhen Gu


12 April 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
XHXiaqin Huang
Xiaqin Huang
JWJunru Wu
Junru Wu
MHMuye He
Muye He
XHXinyu Hou
Xinyu Hou
YWYan Wang
Yan Wang
Yanzuo ChenYanzuo Chen
Yanzuo Chen

29 July 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZWZhongyuan Wang
Zhongyuan Wang
YZYue Zhao
Yue Zhao
YJYan Jiang
Yan Jiang
WLWei Lv
Wei Lv
LWLin Wu
Lin Wu
HXHongliang Xin
Hongliang Xin
The treatment for ischemic stroke is one of the most challenging problems and the therapeutic effect remains unsatisfied due to the poor permeation of drugs across the blood brain barrier (BBB). In this study, HAIYPRH (T7), a peptide that targeted to transferrin receptor (TfR) can mediate the transport of nanocarriers across the BBB, was conjugated to liposomes for ischemic stroke targeting treatment of a novel neuroprotectant (ZL006). T7-conjugated PEGylated liposomes (T7-P-LPs) loaded with ZL006 (T7-P-LPs/ZL006) were showed satisfactory vesicle size and size distribution. Furthermore, the cellular uptake results showed that T7 modification increased liposomes uptake by the brain capillary endothelial cells (BCECs) and little cytotoxicity of liposomes with or without ZL006 was observed. The in vivo biodistribution and near-infrared fluorescence imaging evidenced that T7 modification rendered liposomes significantly enhanced the transport of liposomes across the BBB. The pharmacodynamic study suggested that, T7-P-LPs/ZL006 exhibited reduced infarct volume and ameliorated neurological deficit compared with unmodified liposomes or free ZL006. T7-P-LPs/ZL006 could be targeted to brain and displayed remarkable neuroprotective effects. They could be used as a potential targeted drug delivery system of ischemic stroke treatment.